IGF-1 LR3
Also known as: Long R3 IGF-1, Long-R3-IGF-I, LR3 IGF-1, IGF-1 Long R3
Lower numbers = closer to natural. Higher numbers = more enhanced.
Why this rating?
IGF-1 LR3 is a modified insulin-like growth factor 1 designed to bind the IGF binding proteins (IGFBPs) far less than native IGF-1, so it stays active in circulation much longer (commonly cited around 20-30 hours versus roughly 10 minutes for native IGF-1). Like all IGF-1 it signals through IGF-1R and the PI3K/Akt pathway to drive protein synthesis and cell growth, and it is WADA-prohibited (S2). It carries real hypoglycemia risk (insulin-receptor cross-reactivity) and a theoretical tumour-growth concern. Rated 7 in line with the IGF-1 entry as a potent growth-promoting peptide, though honestly, direct human evidence that IGF-1 meaningfully increases muscle mass is lacking.
Overview
A synthetic analogue of insulin-like growth factor 1 (IGF-1), the main downstream mediator of growth hormone. LR3 ("Long R3") is engineered to bind the IGF binding proteins (IGFBPs) much less than native IGF-1; because most native IGF-1 is normally bound by IGFBPs, cutting that binding leaves more free peptide in circulation and dramatically lengthens its active half-life. It is used in the bodybuilding community for a longer, systemic version of IGF-1's anabolic signalling. Note: the exact LR3 half-life figure widely quoted (~20-30 h) comes from research-reagent/community sources, not an approved-drug label.
Important Warnings
- •WADA prohibited (S2) - will cause a positive test
- •Hypoglycemia risk - always have fast carbs available and never inject fasted
- •Long half-life extends the hypoglycemia window
- •Do NOT use with a personal or family history of cancer
- •Stacking with insulin multiplies the hypoglycemia risk - can be life-threatening
- •No approved human dose exists - community figures only; research-chemical quality varies
Purpose & Use Cases
Systemic Anabolic Signalling
The reduced IGFBP binding and long half-life give a sustained, whole-body IGF-1R signal for protein synthesis and recovery, rather than the brief action of native IGF-1.
Recovery Enhancement
Community use targets faster recovery and tissue repair via prolonged activation of the IGF-1/Akt pathway.
Adjunct to GH / Steroid Use
IGF-1 is typically used to reinforce the anabolic effects of concurrent GH and/or anabolic steroid use, adding a direct downstream growth-factor signal.
Benefits
- Much longer active half-life than native IGF-1 (reduced IGFBP binding)
- Potent activation of the PI3K/Akt/mTOR protein-synthesis pathway
- Systemic (whole-body) rather than fleeting local action
- Does not suppress natural testosterone - no PCT required
- Complements GH and anabolic steroid protocols
Good to Know
The "Long R3" is about escaping IGFBPs
Native IGF-1 is mostly held inactive bound to one of six IGF binding proteins (IGFBPs) and, unbound, clears within roughly 10 minutes. The LR3 modification reduces IGFBP binding so far more of the peptide stays free and active, which is what stretches the effective half-life (widely quoted around 20-30 hours, though that specific figure comes from research/community sources rather than an approved label).
It is insulin-like - hypoglycemia is the acute danger
IGF-1 also binds the insulin receptor and shuttles glucose into cells. That means genuine hypoglycemia risk - shakiness, sweating, confusion and, at worst, loss of consciousness - and the long LR3 action prolongs the window. Eat carbs around the dose, never inject fasted, and keep fast glucose within reach.
Grows all tissues - the organ/cancer caveat
IGF-1 is a growth factor, not an androgen, so it does not suppress the HPTA or need PCT. But "not hormonal" is not "benign": anabolic-misuse reviews list increased liver and kidney mass and edema, and elevated IGF-1 is associated with several cancers and higher mortality at both extremes. The tumour-acceleration concern is theoretical but is the reason to avoid it with any cancer history.
The human muscle-mass evidence is thin
Despite its popularity, reviews of GH/IGF-1/insulin misuse state there is currently no direct in vivo human evidence that IGF-1 significantly increases muscle mass. The mechanism (potent Akt/mTOR activation) is real, but the physique payoff in humans is far less established than the marketing suggests - worth weighing against the hypoglycemia and growth risks.
Dosage Guidelines
| Experience Level | Dosage Range |
|---|---|
| Beginner | 20 – 40 mcg/day |
| Intermediate | 40 – 60 mcg/day |
| Advanced | 60 – 100 mcg/day |
There is no validated human dose - these ranges reflect community practice, not clinical data. Because of the long half-life and insulin-like action, hypoglycemia is a real risk: never inject fasted, keep fast-acting carbohydrate available, and start low. Short cycles (4-6 weeks) are typical to limit receptor desensitisation. Research-chemical quality and correct reconstitution vary by source.
The ~20-30 hour figure is a research/community number, not from a regulatory label, versus roughly 10 minutes for native IGF-1. The extended half-life comes from the LR3 modifications reducing IGFBP binding so more peptide stays free in circulation.
Side Effects
Hypoglycemia
commonIGF-1 cross-reacts with the insulin receptor and drives glucose into cells, so blood sugar can crash: shakiness, sweating, confusion, weakness, and in severe/untreated cases seizures or loss of consciousness. The long LR3 half-life extends this window.
Never inject fasted. Eat carbohydrate around the dose and keep 15-20 g fast glucose within reach.
Organ / Tissue Growth
uncommonIGF-1 stimulates growth in many tissues; reviews of anabolic misuse list increased liver and kidney mass and altered liver function among adverse effects, alongside edema.
Keep doses and cycle lengths conservative; this is a chronic-use concern.
Theoretical Tumour-Growth Concern
rareIGF-1 promotes cell proliferation via the Akt pathway; both low and high IGF-1 levels are associated with increased mortality, and elevated IGF-1 is linked to several cancers. It does not cause cancer but may, in theory, accelerate existing/dormant tumours.
Do not use with a personal or family history of cancer; keep regular health screening.
Edema / Headache / Myalgia / Jaw Pain
uncommonAnabolic-misuse reviews list edema, headaches, jaw pain and myalgia among IGF-1 side effects.
Usually dose-related; reduce or stop if persistent.
Injection Site Reactions
commonRedness, itching, swelling, bruising or soreness at the injection site. Reviews of anabolic misuse identify injection-site reactions as among the most commonly reported adverse effects of IGF-1 use.
Rotate injection sites, use clean subcutaneous technique, and ensure the peptide is properly reconstituted.
Sourcing / Purity Risk
commonAs an unregulated research peptide, actual content and sequence fidelity vary widely by source.
Use tested product with a certificate of analysis; reconstitute correctly (IGF-1 is fragile).
General Mitigation Strategies
The acute danger is hypoglycemia: never inject fasted, eat carbohydrate around the dose, and keep fast glucose within arm's reach. Keep doses conservative and cycles short to limit tissue-growth and desensitisation concerns, and avoid entirely with any personal/family cancer history given the growth-factor mechanism. An honest caveat: reviews of anabolic misuse note there is currently no direct in vivo human evidence that IGF-1 significantly increases muscle mass, so expectations should be tempered against the real risks.
Support Supplements
Ancillary supplements commonly run alongside IGF-1 LR3 to manage side effects, support the target tissue, or fill nutrient demands it creates.
Fast-acting carbohydrates / glucose (dextrose, juice, glucose tabs)
KeyDirect countermeasure for hypoglycemia. IGF-1 activates the insulin receptor and drives glucose into cells, so blood sugar can crash - fast carbs both prevent and rescue a hypo. The long LR3 half-life makes this even more important than with native IGF-1.
- Dose
- Carbs around each injection; keep 15-20 g fast glucose within reach for symptoms (shakiness, sweating, confusion)
- Timing
- Eat carbs before and after the injection. NEVER inject fasted.
- When
- Mandatory, not optional - treat it as core equipment for using IGF-1 LR3.
Post Cycle Therapy (PCT)
IGF-1 does not suppress natural testosterone production - no PCT required for IGF-1 LR3 alone. If stacked with suppressive compounds (e.g. steroids), PCT is needed for those compounds.
How It Works
IGF-1 binds the IGF-1 receptor (IGF-1R), a receptor tyrosine kinase, and is one of the most potent natural activators of the Akt (PI3K/Akt/mTOR) pathway, stimulating cell growth, proliferation and protein synthesis. IGF-1 also binds the insulin receptor, which is the basis of its insulin-like, glucose-lowering effect. Normally most IGF-1 is held in reserve bound to one of six IGF binding proteins (IGFBP 1-6); the LR3 modifications reduce IGFBP binding so more of the analogue circulates free and active, extending its effective half-life far beyond native IGF-1.
Fundamentals
Reference on the practices relevant to IGF-1 LR3: how they are done and where they go wrong. Not a recommendation to use it.
Legal Status
Research chemical (USA). Not FDA-approved: native IGF-1 is approved only as mecasermin/Increlex for severe IGF-1 deficiency, not this analogue. WADA prohibited (S2).
Legal status varies by country and changes over time. This is a general summary, not legal advice.
WADA Status
IGF-1 and all its analogues (including IGF-1 LR3) are prohibited at all times under WADA S2 as growth factors.